The FTC is investigating CVS Caremark and five other pharmacy-benefit managers over how their businesses affect cost and access to prescription drugs
The Federal Trade Commission is probing CVS Caremark , Express Scripts Inc. and other large pharmacy-benefits managers over what impact their business models have on the accessibility and affordability of prescription drugs.
The FTC on Tuesday said it would require the six largest PBMs, which negotiate rebates and fees with drug manufacturers, to provide records and other information about their business practices. The documents will be used to conduct a study of the PBM industry, the FTC said. The compulsory orders are also being sent to UnitedHealth Group Inc.’s OptumRx Inc., Humana Inc., Prime Therapeutics LLC and MedImpact Healthcare Systems Inc.